

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 13th October 2020 12.30 pm
Microsoft Teams
[Join Microsoft Teams Meeting](#)

AGENDA

1.	Apologies for absence	
	<ul style="list-style-type: none"> • Matt Grove 	
2.	Declarations of interest	
3.	Appeals against previous decision	
	<ul style="list-style-type: none"> • Ostenil Plus – deferred until January 2021 	
4.	Minutes from the meeting 14/7/20 Decision summary from 14/7/20	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log	
	<ul style="list-style-type: none"> • update 	Enc.3.
7.	Report from the Formulary sub-group	
	<ul style="list-style-type: none"> • Draft minutes from meeting held on 1/10/20 	Enc.4
8.	ICS update	
	<ul style="list-style-type: none"> • IPMO publication 	Enc.5.
9.	Report from the Medicines Guidelines and Use Group	
	<ul style="list-style-type: none"> • Draft minutes from meeting held on 7/9/20 • Guidance/documents for approval: <ul style="list-style-type: none"> ○ Northern England Evaluation and Lipid Intensification guideline (NEELI) – Dr. Pattman to attend. ○ Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities – approved by chair's action. ○ Amiodarone SCG ○ Agomelatine ○ Stoma ○ Paediatric nephrotic syndrome ○ Sativex • Guidance to retire: <ul style="list-style-type: none"> ○ Hypertension guidelines 	Enc.6. Enc.7. On website Enc.8. Enc.9. Enc.10. Enc.11. Enc.12.
10.	Review of survey by Epilepsy Society and Young Epilepsy https://www.youngepilepsy.org.uk/dmdocuments/Valproate-Survey-Final-report.pdf	
11.	Opiate/pain management sub-group	
	<ul style="list-style-type: none"> • Update from meeting held on 12/8/20 • Qtr 1 data 	Enc.13. Enc.14.

12.	<p>RMOCs</p> <ul style="list-style-type: none"> • Verbal update 	
13.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/</p> <ul style="list-style-type: none"> • Infliximab Subcutaneous (Remsima®) guidance - updated http://ntag.nhs.uk/docs/rec/NTAG-Decision-Summary-Infliximab-subcutaneous-Remsima-updated-Aug-2020.pdf <p>The following recommendations were finalised by NTAG at their meeting on the 1st September 2020 and are now available on the website www.ntag.nhs.uk:</p> <ul style="list-style-type: none"> • Brolucizumab for wAMD • Liposuction for Lymphoedema and Lipoedema • Semaglutide (oral) for type 2 diabetes <p>The following recommendations were updated by NTAG at their meeting on the 1st September 2020 and are now available on the website:</p> <ul style="list-style-type: none"> • Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence • Airsonett® laminar flow device for treatment of uncontrolled allergic asthma <p>The following recommendations were archived by NTAG at their meeting on the 1st September 2020 as now superseded by NICE TA or NHSE guidance:</p> <ul style="list-style-type: none"> • Gastro-intestinal stimulation with the Enterra™ device for Gastroparesis (NETAG) <p>The June 2020 Minutes are now also available on the site here. The work plan of the group has been updated here.</p>	
14.	<p>NICE Technology Appraisals and EAMS published since last meeting</p> <ul style="list-style-type: none"> • (EAMS) : Dupilumab in the treatment of children aged 6 to 11 years of age with severe atopic dermatitis (allergic eczema) • (EAMS) : Nivolumab for treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal cancer after prior chemotherapy • Early access to medicines scheme (EAMS) scientific opinion: Avelumab in the treatment of bladder cancer • TA640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant • TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma • TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia • TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer • TA644 Entrectinib for treating NTRK fusion-positive solid tumours • TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma • TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma • TA651 Naldemedine for treating opioid-induced constipation • TA650 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma – negative appraisal 	

15.	<p>NHS England</p> <ul style="list-style-type: none"> • Specialised Services circulars <ul style="list-style-type: none"> ○ SSC2171 - NICE Technology Appraisal Final Appraisal Determination - polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma ○ SSC2173 - Specialised Commissioning Update September to November 2020 ○ SSC2175 - Avelumab as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed following first-line platinum-based induction chemotherapy ○ SSC2176 - NICE Technology Appraisal Final Appraisal Determination: osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (rapid review of TA621) ○ SSC2177 - Hereditary Angioedema (HAE) Supply disruption – Danazol – 100mg-200mg capsules ○ SSC2178 - nivolumab adv non-squamous NSCLC after chemotherapy 	Enc.15.
16.	Chairman's action	
17.	Any other business	
18.	Date, time and venue of next meetings (to discuss).	